2026 · 3rd Quarter (July 1 - Sep 30)
Filed by ARTEMIS POLICY GROUP LLC.
Open official filingSource-reported fields
Literal source text
Issues related to reimbursement for hemophilia services and treatments in Medicare: comments on proposed HOPPS rule (CMS-1850-P) Issues related to reimbursement for hemophilia services and treatments in Medicaid Implementation of H.R. 1, One Big Beautiful Bill Act Implementation of Medicaid Community Engagement requirements: comments on Medicaid community engagement IFR (CMS-2454-IFC)
Literal federal measure citations: H.R. 1
Implementation of H.R. 1, One Big Beautiful Bill Act Affordable Care Act implementation Coverage of hemophilia treatments and services in private insurance plans: comments on essential health benefits review, RIN 0938-AW02 Policies related to co-pay accumulators and maximizers, including the HELP Copays Act (S 864, HR 6423) Policies related to the operations of pharmacy benefits managers Private insurance policies that discriminate coverage for high-cost drugs and use of patient assistance programs, also known as Alternative Funding Programs
Issues related to participation in the 340B Drug Discount Program Polices related to PBMs and drug cost transparency 340B Drug Pricing Integrity and Affordability for Patients Act discussion draft SECURE 340B Act, HR 9599 SUSTAIN 340B Act, S. 5244 Comments on Senate Finance Committee RFI on drug pricing
Funding for federal hemophilia programs at CDC and HRSA for FY27 Funding and staffing for the CDC Division of Blood Disorders and Public Health Genomics: Letter to CDC Director Erica Schwartz re Division of Blood Disorders & Public Health Genomics
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.
